340B Better Together? PhRMA Partners With Community Health Centers On Legislative Reforms
PhRMA's collaboration with the provider group may help alleviate concerns that legislators' pursuit of pharma-backed 340B reforms would pit lawmakers against hospitals that serve as a safety net for vulnerable patients.
You may also be interested in...
CMS guidance on the Medicaid Drug Rebate Program, best price and drug importation from 2020 should make it less attractive for states to implement importation programs and help pharma.
Stakeholders differ on whether the rapid growth in spending is to be expected, given the realities in health care and specialty drug costs, or that the data underscores the need for oversight and reform of the 340B program.
Research is published as the US Congress gears up to explore reforms of the 340B program. The findings align with pharma’s push to ‘share the savings’ but are not currently typical in the program, the Pharmaceutical Research and Manufacturers of America maintains.